联合基线中性粒细胞增多与FDG PET原发肿瘤SUVpeak的评分与局部晚期宫颈癌结局相关
本研究回顾性分析2006至2013年接受根治性放化疗联合图像引导自适应近距离放疗的局部晚期宫颈癌患者108例,分为训练集69例和验证集39例。联合基线中性粒细胞增多与PET放射组学指数定义的中性粒细胞SUV分级(NSG)评分,在训练集中NSG=2与局部控制(HR=7.5,p<0.001)和总生存(HR=5.8,p=0.001)独立相关,验证集结果有前景。
要点
- 训练集中SUVpeak为最具局部控制预测价值的生物标志物(td-AUC=0.75)。
- 训练集中NSG=2与低局部控制概率独立相关(HR=7.5,p<0.001)。
- 训练集中NSG=2与低总生存概率独立相关(HR=5.8,p=0.001)。
核心结论
- 这种联合基线中性粒细胞增多与PET生物标志物的创新评分方法提供了独立的预后因素,值得进一步临床研究。
研究设计与样本
- 回顾性分析2006至2013年接受根治性放化疗联合图像引导自适应近距离放疗的局部晚期宫颈癌患者。
- 按所用PET设备分为训练集(n=69)和验证集(n=39),共分析108例患者数据。
- 在PET图像上半自动勾画原发肿瘤,计算11个放射组学特征,采用3年局部控制的时间依赖AUC选择PET放射组学指数。
- 中性粒细胞SUV分级(NSG=0、1或2)定义为以下风险因素的数目:中性粒细胞增多(中性粒细胞计数>7 G/L)和基于PET放射组学指数定义的高风险。
主要发现
- 训练集估计3年局部控制率为72%,验证集为65%。
- 训练集中SUVpeak被选为最具局部控制预测价值的生物标志物(td-AUC=0.75),且与中性粒细胞增多独立(p=0.119)。
- 训练集中中性粒细胞增多(HR=2.6)、高风险SUVpeak(SUVpeak>10,HR=4.4)和NSG=2(HR=9.2)与低局部控制概率相关。
- 训练集多变量分析中NSG=2与低局部控制概率独立相关(HR=7.5,p<0.001),与低总生存概率独立相关(HR=5.8,p=0.001)。
- 验证集结果有前景:总生存HR=5.2,局部控制HR=3.5,p<0.02。
关键数值与推荐
- 中性粒细胞增多的阈值为中性粒细胞计数>7 G/L。
- 高风险SUVpeak的阈值为SUVpeak>10。
- NSG评分取值为0、1或2,为中性粒细胞增多和高风险PET放射组学指数两个风险因素的数目。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文为回顾性分析。
- 原文结论称该评分方法值得进一步临床研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We investigated whether a score combining baseline neutrophilia and a PET biomarker could predict outcome in patients with locally advanced cervical cancer (LACC). METHODS: Patients homogeneously treated with definitive chemoradiation plus image-guided adaptive brachytherapy (IGABT) between 2006 and 2013 were analyzed retrospectively. We divided patients into two groups depending on the PET device used: a training set (TS) and a validation set (VS). Primary tumors were semi-automatically delineated on PET images, and 11 radiomics features were calculated (LIFEx software). A PET radiomic index was selected using the time-dependent area under the curve (td-AUC) for 3-year local control (LC). We defined the neutrophil SUV grade (NSG = 0, 1 or 2) score as the number of risk factors among (i) neutrophilia (neutrophil count >7 G/L) and (ii) high risk defined from the PET radiomic index. The NSG prognostic value was evaluated for LC and overall survival (OS). RESULTS: Data from 108 patients were analyzed. Estimated 3-year LC was 72% in the TS (n = 69) and 65% in the VS (n = 39). In the TS, SUVpeak was selected as the most LC-predictive biomarker (td-AUC = 0.75), and was independent from neutrophilia (p = 0.119). Neutrophilia (HR = 2.6), high-risk SUVpeak (SUVpeak > 10, HR = 4.4) and NSG = 2 (HR = 9.2) were associated with low probability of LC in TS. In multivariate analysis, NSG = 2 was independently associated with low probability of LC (HR = 7.5, p < 0.001) and OS (HR = 5.8, p = 0.001) in the TS. Results obtained in the VS (HR = 5.2 for OS and 3.5 for LC, p < 0.02) were promising. CONCLUSION: This innovative scoring approach combining baseline neutrophilia and a PET biomarker provides an independent prognostic factor to consider for further clinical investigations.
引用
- Schernberg A, Reuze S, Orlhac F, et al. A score combining baseline neutrophilia and primary tumor SUVpeak measured from FDG PET is associated with outcome in locally advanced cervical cancer. Eur J Nucl Med Mol Imaging. 2017. PMID: 28916879. doi:10.1007/s00259-017-3824-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。